Skeljungur hf.
A reduction of Skeljungur hf.´s share capital has been registered at a nominal value of ISK 49.641.892 but shareholders approved at the AGM March 4, 2021 to reduce the company´s share capital through the cancellation of all the company´s own shares. Legal conditions for such a reduction have now been met so the company will now execute the reduction of share capital.
Registered share capital after the reduction is of nominal value ISK 1.936.033.774 but was before the reduction nominal value of ISK 1.985.675.666. Each share corresponds to one – 1 – ISK in nominal value. Each share of one króna – shall carry one vote.
For further information please contact Árni Pétur Jónsson, CEO, fjarfestar@skeljungur.is.
www.skeljungur.is
https://www.linkedin.com/company/skeljungur-hf/
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ALK Abello19.12.2025 22:46:46 CET | Press release
Major shareholder announcement
ALK Abello19.12.2025 22:46:46 CET | Pressemeddelelse
Storaktionærmeddelelse
Zealand Pharma19.12.2025 22:00:00 CET | Press release
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Boehringer Ingelheim Limited19.12.2025 21:10:00 CET | Press release
U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
Novartis Pharma AG19.12.2025 20:30:06 CET | Press release
Novartis and US government reach agreement on lowering drug prices in the US
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
